Search Within

Advanced Practice Providers

  1. "GSK Faculty"
Formats
  1. Meeting Abstract (153)
  2. Journal Article (79)
  3. Research Letter (3)
  4. Editorial (1)
  5. Miscellaneous (1)
Groups
  1. GSK Faculty (237)
  2. Department of Medicine (200)
  3. Nursing (196)
  4. Center for Hematologic Malignancies (145)
  5. Hematologic Malignancies, Division of (138)
  6. Sloan Kettering Institute Faculty (108)

More Groups

People
  1. Renier Brentjens (52)
  2. Elizabeth Halton (48)
  3. Jae Park (47)
  4. Isabelle Riviere (38)
  5. Richard O'Reilly (37)
  6. Maria Palomba (36)

More People

Years
  1. 2025 (2)
  2. 2024 (15)
  3. 2023 (13)
  4. 2022 (18)
  5. 2021 (19)
  6. 2020 (17)

More Years

Publications
  1. Blood (54)
  2. Journal of Clinical Oncology (45)
  3. Biology of Blood and Marrow Transplantation (14)
  4. Neuro-Oncology (13)
  5. Bone Marrow Transplantation (7)
  6. Cancer Research (7)

More Publications

Publishers
  1. American Society of Hematology (58)
  2. American Society of Clinical Oncology (46)
  3. Elsevier Inc. (22)
  4. American Association for Cancer Research (21)
  5. Oxford University Press (16)
  6. Nature Publishing Group (15)

More Publishers

Results (237)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies
    Meeting Abstract

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)
    Meeting Abstract

    Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase 1 dose-escalation trial using convection-enhanced delivery of radiolabeled monoclonal antibody for diffuse intrinsic pontine glioma following external radiation therapy
    Meeting Abstract

    Souweidane, M. M.; Kramer, K.; Pandit-Taskar, N.; Haque, S.; Zanzonico, P.; Carrasquillo, J. A.; Lyashchenko, S. K.; Thakur, S. B.; Khakoo, Y.; Donzelli, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab
    Journal Article

    Adusumilli, P. S.; Zauderer, M. G.; Rivière, I.; Solomon, S. B.; Rusch, V. W.; O'Cearbhaill, R. E.; Zhu, A.; Cheema, W.; Chintala, N. K.; Halton, E.; more...
    Cancer Discovery (2021)

    Fulltext@MSK | Save
  • Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy
    Journal Article

    Tamari, R.; Politikos, I.; Knorr, D. A.; Vardhana, S. A.; Young, J. C.; Marcello, L. T.; Doddi, S.; Devlin, S. M.; Ramanathan, L. V.; Pessin, M. S.; more...
    Blood Cancer Discovery (2021)

    Fulltext@MSK | Save
  • Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia
    Research Letter

    Perica, K.; Flynn, J.; Curran, K. J.; Rivere, I.; Wang, X.; Senechal, B.; Halton, E.; Diamonte, C.; Pineda, J.; Bernal, Y.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save